Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder to Reduce Symptoms and Improve Cognition

NCT03043820 is registered in ClinicalTrials.gov with Iris Sommer as lead sponsor.

NCT NCT03043820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03043820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder to Reduce Symptoms and Improve Cognition
Lead sponsor
Iris Sommer
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2016
Completion date
July 1, 2021
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psychosis nos, schizoaffective disorder, schizophrenia, schizophreniform disorder